Paolo Borghetti
Overview
Explore the profile of Paolo Borghetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Facheris G, Cossali G, Imbrescia J, La Mattina S, Mataj E, Meli N, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075721
Introduction And Aim: Stage III Non-Small Cell Lung Cancer (NSCLC) has a poor prognosis, with median survival ranging from 9 to 34 months. The PACIFIC trial demonstrated that durvalumab after...
2.
Corrao G, Marvaso G, Zaffaroni M, Vincini M, Badellino S, Borghetti P, et al.
Radiol Med
. 2025 Mar;
PMID: 40072805
Aim: Despite the widespread use of immunotherapy (IO) and targeted therapy (TT) in clinical practice, data on toxicity in combination with SBRT are lacking, largely based on retrospective studies and...
3.
Cortiula F, Kutiel T, Hsu M, Hendriks L, Nassar A, Moskovitz M, et al.
Eur J Cancer
. 2025 Feb;
219:115302.
PMID: 39987799
Introduction: The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patients, often...
4.
Borghetti P, Ramella S, Ricardi U
Front Oncol
. 2025 Feb;
14:1541527.
PMID: 39927114
Small cell lung cancer (SCLC) is an aggressive tumor that presents in most cases as a metastatic disease. The prognosis is poor, but the advent of immunotherapy has rekindled hopes...
5.
Guerini A, Mataj E, Borghetti P, Triggiani L, Pegurri L, Nici S, et al.
Adv Radiat Oncol
. 2025 Feb;
10(3):101696.
PMID: 39911722
Purpose: Multiple myeloma (MM) tends to develop resistance to systemic therapy through multiple mechanisms that might as well induce radioresistance, as suggested by preclinical studies. The aim of the present...
6.
Catania C, Proto C, Bennati C, Grisanti S, Colantonio I, Petrella F, et al.
Crit Rev Oncol Hematol
. 2025 Feb;
208:104633.
PMID: 39900317
Introduction: During the recent INTERACTION group congress held on February 16-17, 2024, in Milan, Italy, many aspects of early-stage lung cancer treatment were explored. This review delves into perioperative treatment,...
7.
Bianchera A, Borghetti P, Ravanetti F, Bertocchi L, De Angelis E, Bettini R
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684203
Hyaluronic acid (HA) is a key component of synovial fluid as it plays a crucial role in joint physiology. Its biological activity is influenced by molecular weight, local concentration, and...
8.
Bruni A, Scotti V, Zerella M, Bertolini F, Imbrescia J, Olmetto E, et al.
Curr Oncol
. 2024 Nov;
31(11):6791-6802.
PMID: 39590132
Background: Extensive-stage small-cell lung cancer (ES-SCLC) treatment has recently been revolutionized by the advent of immune checkpoint inhibitors. This survey was conducted to evaluate the current pattern of care among...
9.
De Angelis E, Borghetti P, Passeri B, Cavalli V, Ferrari L, Andrani M, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457703
The porcine intestinal epithelium plays a fundamental role as a defence interface against pathogens. Its alteration can cause severe inflammatory conditions and diseases. Hyperosmotic stress under physiological conditions and upon...
10.
Nardone V, Bruni A, Franceschini D, Marini B, Vagge S, Ciammella P, et al.
Radiol Med
. 2024 Aug;
129(11):1700-1709.
PMID: 39215945
Background: Recently, the PORT-C and LUNG-ART trials, which evaluated the role of postoperative radiation therapy (PORT), have significantly altered the treatment landscape for NSCLC pN2 patients who previously underwent surgery....